| 高雄醫學大學 |
2009 |
The eccicacy of pegylated interferon plus ribavirin combination therapy in chronic hepatiti s C patients with hepatocelular carcinoma post curative therapies
|
黃志富;余明隆;戴嘉言;侯乃仁;黃釧峰;丘長富;黃駿逸;葉明倫;謝孟軒;楊正福;林子堯;陳信成;莊萬龍 |
| 高雄醫學大學 |
2009 |
甲狀腺抗體對於慢性C型肝炎接受長效型干擾素合併Ribavirin治療的影響
|
黃兆寬;戴嘉言;黃志富;謝明彥;侯乃仁;林文一;林子堯;陳信成;王良彥;莊萬龍;余明隆 |
| 高雄醫學大學 |
2009 |
肝功能指數為新陳代謝症候群與胰島素抗性之重要因子
|
林文一;余明隆;楊正福;謝孟軒;黃兆寬;張寧家;林嘉益;黃釧峰;林幸宜;王肇齡;侯乃仁;黃志富;戴嘉言;張文宇;莊萬龍 |
| 高雄醫學大學 |
2008 |
C型肝炎病毒血症與較低之血清三酸甘油脂及膽固醇值相關:一社區研究
|
戴嘉言;莊萬龍;何啟功;謝明彥;黃志富;李立柏;侯乃仁;林子堯;陳信成;謝明裕;王良彥;蔡榮發;張文宇;余明隆; Dai, CY;Chuang, WL;Ho, CK;Hsieh, MY;Huang, JF;Lee, LP;Hou, NJ;Lin, ZY;Chen, SC;Hsieh, MY;Wang, LY;Tsai, JF;Chang, WY;Yu, ML |
| 高雄醫學大學 |
2007 |
Links between triglyceride levels; hepatitis C virus infection and diabetes.
|
戴嘉言;黃志富;謝明彥;李立柏;侯乃仁;余明隆;莊萬龍 ; Dai CY;Huang JF;Hsieh MY;Lee LP;Hou NJ;Yu ML;Chuang WL |
| 高雄醫學大學 |
2007 |
(在台灣慢性C型肝炎之肝臟脂肪變性及肝臟纖維化)
|
謝孟軒;李立柏;謝明彥;蔡坤寶;黃志富;侯乃仁;陳信成;林子堯;謝明裕;王良彥;戴嘉言;莊萬龍;余明隆 ; Hsieh MH;Lee LP;Hsieh MY;Tsai KB;Huang JF;Hou NJ;Chen SC;Lin ZY;Hsieh MY;Wang LY;Dai CY;Chuang WL;Yu ML |
| 高雄醫學大學 |
2007 |
The HBV Infection Among Aboriginal Children 20 Years After Immunization In Taiwan
|
莊萬龍;余明隆;戴嘉言;何啟功;黃釧峰;侯乃仁;李立柏;謝明彥;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇 |
| 高雄醫學大學 |
2007 |
干安能治療B型肝炎引起失償非肝硬化病患早期死亡率及反應-以MELD及INDEX指標評估
|
戴嘉言;余明隆;侯乃仁;謝明彥;李立柏;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2007 |
The antinuclear antibody is associated with lower RNA levels of hepatitis C virus and more advanced fibrosis in chronic hepatitis C patients
|
謝明彥;黃志富;侯乃仁;戴嘉言;李立柏;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍;余明隆 |
| 高雄醫學大學 |
2007 |
Almost all HCV G2 Pts With Rapid Virologic Response at Wk 4 Achieve a SVR With 16 Wks of Treatment
|
余明隆;戴嘉言;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2007 |
Different Features In Liver Histopathology Of HCV Monoinfection And HCV/HBV Dual Infection
|
李立柏;余明隆;戴嘉言;侯乃仁;謝明彥;林子堯;陳信成;謝明裕;王良彥;Chen, Tong-Jong;張文宇;莊萬龍 |
| 高雄醫學大學 |
2007 |
The Seroprevalence Of HBV And HCV Infection In Southern Taiwan- Large Scale Community-Based Study
|
莊萬龍;余明隆;戴嘉言;林嘉益;侯乃仁;李立柏;謝明彥;黃志富;謝明裕;張文宇 |
| 高雄醫學大學 |
2007 |
Transforming Growth Factor-Beta 1 Gene Polymorphisms In High Dose IFN/Ribavirin treated CHC Patients
|
戴嘉言;余明隆;張文宇;李立柏;潘文正;侯乃仁;謝明彥;黃志富;陳信成;林子堯;謝明裕;王良彥;莊萬龍 |
| 高雄醫學大學 |
2007 |
Early Mortality And Responses In Non-Cirrhotic Decompensated CHB Patients With Lamivudine Therapy
|
戴嘉言;余明隆;侯乃仁;謝明彥;李立柏;黃志富;陳信成;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2007 |
EARLY MORTALITY AND RESPONSES IN NON-CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS B-RELATED DECOMPENSATION WITH LAMIVUDINE THERAPY: EVALUATION OF MELD AND INDEX SCORING SYSTEMS AS PROGNOSTIC PREDICTORS
|
戴嘉言;余明隆;侯乃仁;謝明彥;李立柏;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2007 |
The presence of Antinuclear Antibody is associated with a negative response to combination therapy with peginterferon and ribavirin for patients without genotype 1 chronic hepatitis C infection
|
謝明彥;戴嘉言;黃志富;莊萬龍;侯乃仁;李立柏;陳信成;謝明裕;王良彥;張文宇;余明隆 |
| 高雄醫學大學 |
2007 |
High chance of cure in HCV genotype 1 patients with a low viral load achieving an RVR treated for 24 wks with pegylated interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS): Prospective, randomized, controlled study comparing 24 & 48 wks of treatm
|
余明隆;戴嘉言;黃志富;李立柏;謝明彥;丘長富;侯乃仁;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍* |
| 高雄醫學大學 |
2006 |
Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
|
余明隆;戴嘉言;李立柏;謝明彥;侯乃仁;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 ; Yu ML;Dai CY;Lee LP;Hsieh MY;Hou NJ;Huang JF;Lin ZY;Chen SC;Hsieh MY;Wang LY;Chang WY;Chuang WL |
| 高雄醫學大學 |
2006 |
Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.
|
戴嘉言;莊萬龍;張文宇;陳信成;李立柏;謝明彥;侯乃仁;林子堯;黃志富;謝明裕;王良彥;余明隆 ; Dai CY;Chuang WL;Chang WY;Chen SC;Lee LP;Hsieh MY;Hou NJ;Lin ZY;Huang JF;Hsieh MY;Wang LY;Yu ML |
| 高雄醫學大學 |
2006 |
A randomized study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C
|
余明隆;戴嘉言;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2006 |
Predictors for early mortality in lamivudine-treated patients with chronic hepatitis B-related decompensation in Taiwan ”has been accepted for poster presentation at the forthcoming.
|
戴嘉言;莊萬龍;李立柏;謝明裕;侯乃仁;陳信成;林子堯;謝明彥;王良彥;黃志富;張文宇;余明隆 |
| 高雄醫學大學 |
2006 |
CLINICAL SIGNIFICANCE OF ERYTHROPOIETIN IN CHRONIC HEPATITIS C PATIENTS
|
侯乃仁;余明隆;戴嘉言;林子堯;張文宇;莊萬龍 |
| 高雄醫學大學 |
2006 |
A randomized, controlled, open-label study of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 vs. 24 weeks in patients with genotype 2 hepatitis C infection
|
余明隆;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明彥;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2006 |
Predictors for early mortality in lamivudine-treated patients with chronic hepatitis B-related decompensation in Taiwan ”has been accepted for poster presentation at the forthcoming.
|
戴嘉言;莊萬龍;李立柏;謝明裕;侯乃仁;陳信成;林子堯;謝明彥;王良彥;黃志富;張文宇;余明隆 |
| 高雄醫學大學 |
2005 |
Tumor necrosis factor alpha promoter polymorphism at position-308 predicts hepatitis C virus response to combination therapy with high dose interferon and ribavirin
|
戴嘉言;余明隆;莊萬龍;李立柏;謝明裕;侯乃仁;張文宇 ; Dai CY;Yu ML;Chuang WL;Lee LP;Hsieh MY;Hou NJ;Chang WY |
